Login to Your Account



BsUFA II tradeoffs could delay some biosimilar guidances

By Mari Serebrov
Regulatory Editor

Monday, September 19, 2016

FDA commitments in the BsUFA II goals letter to improve communication, transparency and staffing are getting high marks from industry, which sees those steps as essential to bettering the review of biosimilars for the U.S. market.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription